Researchers at ATRI are committed to advancing the fight against Alzheimer's disease. A key part of this effort is ensuring that data from clinical trials is shared broadly and openly. This allows other scientists to analyze the data and potentially make new discoveries.
In a recent paper published in the Journal of Prevention of Alzheimer's Disease, Gustavo A. Jimenez-Maggiora and others, described their approach to sharing data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies.
The A4 and LEARN studies were designed to evaluate the effectiveness of a drug called solanezumab in slowing cognitive decline in people with pre-symptomatic Alzheimer's disease. The studies collected a wealth of data from over 7,000 participants, including clinical, cognitive, neuroimaging, and genetic measures.
Our researchers began sharing data from the A4 and LEARN studies in December 2018. As of May 8, 2024, they have received over 1,500 data access requests from investigators and citizen scientists around the world. They have also identified nearly 50 peer-reviewed publications that acknowledge the A4/LEARN studies.
These results demonstrate the feasibility and value of sharing data from Alzheimer's disease trials early and widely. By making data available to other researchers, we can accelerate progress in the development of new treatments for this devastating disease.